WAR ON CANCER
MIDDLE EAST

May 1st
2018
Dubai, UAE
INTRODUCTION

WAR ON CANCER MIDDLE EAST
Opening a new frontier
May 01st 2018 • Dubai

Cancer in the Middle East is on the rise. Poor healthcare access, late presentation and a change in lifestyles have meant that cancer incidence is due to rise faster than any region in the world by 2030, to almost double what it was in 2012. Yet poor data on cancer incidence, mortality and patient satisfaction, makes meeting the challenge all the more difficult. For patients, overcoming the fatalism and stigma surrounding cancer is an additional barrier to treatment.

In 2015, The Economist Events declared war on cancer at an inaugural summit in Hong Kong. Since then, we have taken the conversation from Boston to London, Singapore to Oslo, to explore the most pressing issues in policy and financing, treatment and care across the globe. Bringing together a diverse audience from the policy, finance, and medical communities, our aim has been to share best practice and to catalyse action; breaking down silos to confront the enormous challenge cancer presents.

War on Cancer Middle East 2018 aims to explore the state of cancer care in the region, sharing and comparing different approaches as well as exchanging insights from the region and the rest of the world. Through robust panel debates, case studies, and strategy sessions, we will explore the evolving policy solutions to the increase in cancer incidence, as well as the innovative financing models that can bridge the funding gap for treatment. From basic epidemiological data collection, prevention, screening and early detection to diagnosis, treatment and access to effective palliative care, it will mine cost-effective, results-driven strategies for mitigating the disease, with an emphasis on improving equity of access, the quality, delivery and affordability of care. Our case studies will tackle some of the issues surrounding fatalism and stigma, while also crucially ensuring that the patients themselves are front and centre of the discussion. We will bring together leaders from government, healthcare, academia and industry to assess how the Middle East can manage its cancer burden.

Conference chairs
Charles Goddard, editorial director, Asia-Pacific, The Economist Intelligence Unit
Vivek Muthu, chair, The Economist Intelligence Unit Healthcare
08.30  Registration and networking refreshments

09:00  Chair’s opening remarks: A global war on cancer
In this opening session, the chair will explore some of the best practices gleaned from the global War on Cancer initiative, and set out the state of play in the Middle East. The chair will encourage participants to collaborate each other to break down silos and implement cancer control programmes that truly benefit the patient and deliver high-quality outcomes.

09.10  The state of play: Cancer control in the Middle East
What countries have effective cancer control plans in place, and how can others develop their own? This session will be a deep-dive into the state of cancer care in the region – areas of success, as well as where there is room for improvement.

Rifat Atun
Professor of global health systems, Harvard University

Norajoublatt
Chair, Children Cancer Center, Lebanon

H.R.H. Princess Dina Mired
President-elect, Union for International Cancer Control (UICC)

H.R.H. Princess Ghida al-Talal
Chair, King Hussein Cancer Center

09.55  Why we’re here: The patient’s perspective
Through two spotlights, we will ground our discussion in what really matters – the patient. These brief and effective case studies will bring inspirational individuals and patient groups into the discussion, and inform the discussion and the plan for the way ahead.

Lama Riachi
Founder, Blessed support group

Yuthar Al-Rawahi
Founder, Oman Cancer Association

10.15  Networking break
10.45  Head to head interview: From a GC to a CEO
With a booming youth population and ambitious plans for the future, many Middle Eastern countries have set their sights on progress in the fight against cancer. Which national cancer control plans have been successful, and how can they improve? What can policymakers learn from each other, and are there opportunities for transnational cooperation in healthcare? How have policymakers adapted to a large number of migrant workers entering the healthcare system?

11.35  Panel discussion: Early detection and screening
Late presentation is an acute problem in the Middle East, meaning that early detection must be a core part of any cancer control programme. Yet screening to detect disease early on requires a robust system of cancer treatment which is affordable and accessible. In addition, the evidence for effective methods has traditionally been unreliable. What are the advantages and disadvantages of different methods? How can healthcare resources manage an increase in cancer cases and false diagnosis?

Sawsan Al Madhi
Director general, Friends of Cancer Patients

Fatina Al Tahan
Director, national cancer control programme, Government of Saudi Arabia

Eman Almohawes
Head of early detection programme, Saudi Cancer Foundation

12.20  Networking Lunch

13.20  Strategy sessions: Multi-stakeholder collaboration
Delegates will choose to attend one of two concurrent breakout sessions to brainstorm how stakeholders can collaborate to solve some of the regional issues that are hampering progress. Delegates can choose which subject is most relevant to their own experience, and sessions will be led by an Economist editor and guest speakers.

Strategy session 1: Filling in the data gaps
Data forms the bedrock of our cancer control programmes, allowing us to assess where improvement is needed, from policymaking to pricing, access to treatment. Yet data is woefully patchy in the Middle East – how can this be improved? More difficult than incidence is measuring coverage, as well as patient satisfaction and mortality. What does it take to develop effective cancer data, and how can we accelerate this development?
Programme

Strategysession 2: Taxing tobacco and other strategies
Lung cancer is the most common form of cancer amongst men in the Middle East, and tobacco smoke causes more than 85% of lung cancer cases. An effective strategy for reducing lung cancer incidence in other countries has been to implement a ban on smoking in public places, but there are also calls to go further – and bring into a force a tobacco tax to disincentivise consumers from purchasing cigarettes. What other strategies could be brought to bear in order to reduce lung cancer incidence?

14.00 Panel discussion: Treatment and palliation
Access to treatment for cancer is vital, yet it is a highly specialised and costly affair. For those in remote areas, this poses a problem – how can access to care be improved? On the other hand, while treatment must be a priority, palliation cannot fall to the wayside. Palliation is critical for patient wellbeing, and is too often overlooked. How can access to treatment and palliation be delivered in the region, what is currently available, and where is there need for improvement?

Hamdy Azim
Founder, Cairo Oncology Center

Mohammad Bushnaq
President, Jordanian Palliative Care and Pain Management Society

14:40 Why we’re here: The patient’s perspective
Through two spotlights, we will ground our discussion in what really matters – the patient. These brief and effective case studies will bring inspirational individuals and patient groups into the discussion, and inform the discussion and the plan for the way ahead.

15:00 Networking break

15.30 Panel discussion: Financing the gap
Many countries in the region boast universal health coverage for nationals, yet migrant workers make up large proportions of the workforce—close to 50% in GCC countries. How can governments engage private-sector insurers and investors to ensure that cancer control is affordable throughout the region, reducing high out-of-pocket payments? How can public-private partnerships play a role in doing so? What regulatory constraints are currently in place?

Michael Bitzer
Chief executive officer, Daman

#WarOnCancer
16.15  **Middle East 2050**
In this session, we imagine the Middle East healthcare landscape in 2050. What previously unimaginable innovations in cancer care will have come to fruition? What will the state of healthcare be, from access to outcomes? This conversation will give us insight into the technologies that will revolutionise the way we live over the coming decades.

**Richard Sullivan**
Professor of cancer and global health, KCL

16.35  **Panel discussion: Innovation in health systems**
Following on from a futuristic look into 2050, we gather a panel to explore the innovations in healthcare that we can implement today. Mobile health (m-health) offers huge potential for difficult-to-reach areas, while a growing population will require countries to innovate in order to create a more flexible health system, fit for purpose in the 21st century. How can we improve access and affordability through technology? Is the personalisation of medicine the new frontier for oncology? How can policymakers ensure they are open to new developments, while ensuring such technologies are adequately regulated?

**Shamsheer Vayalil**
Managing director, VPS Healthcare

**Pamela Paulk**
President, Johns Hopkins Medicine’s International Enterprises

**Sinan Atlig**
Regional leader, Innovative Health Business (PIH), Africa and Middle East, Pfizer

**Özlem Düzen Fidancı**
Chief executive, Middle East and Turkey, Philips

17.10  **Closing keynote interview: Middle East and the world**
How can the learnings from today's event be brought to bear in future events, both in the region and across the world? How could The Economist develop its programme in the region, as well as bring global insights to the Middle East? This session will consider the major takeaways from the day's event, and where the discussion goes next in order to make progress.
17.10  Closing remarks
In his closing remarks, the conference chair reflects on key messages discussed during the day, and describes next steps the cancer ecosystem must take to move the mark forward in the war on cancer.

17.40  Networking reception: Meet the moderators

* Please note agenda and speakers are subject to change.
MORE INFORMATION

To book your place, visit
waroncancermiddleeast.economist.com

Alternatively,
email us at - emeaevents@economist.com
or
call +44 (0)20 7576 8118

VENUE DETAILS

TAJ DUBAI

Taj Dubai, Damac Maison, Dubai Mall Street - Dubai

FOLLOW US

Continue the conversation on Twitter using #WarOnCancer
@EconomistEvents.
SPONSORS

Gold Sponsors:

- Roche
- PhRMA
- PhRMAG

Silver Sponsor:

- Pfizer

SUPPORTING ORGANISATIONS & ASSOCIATIONS

- AmCham and UICC
- EACR

MEDIA PARTNERS

- Asian Healthcare
- Hospitals
- Middle East Health
- Oncology Central